본 보고서는 HER3 억제제의 주요 7개 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에 대한 조사 분석을 통해 각 지역 시장 규모와 예측, 현재의 치료법, 신약, 미충족 수요(Unmet Needs) 등의 정보를 제공합니다.
DelveInsight's "HER3 inhibitors - Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the HER3 inhibitors, historical and Competitive Landscape as well as the HER3 inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The HER3 inhibitors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM HER3 inhibitors market size from 2020 to 2034. The report also covers current HER3 inhibitors treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Study Period: 2020-2034
HER3 Inhibitors Overview
HER3, also known as ErbB3, is a member of the ErbB/HER family of receptor tyrosine kinases, which also includes EGFR (HER1), HER2, and HER4. Unlike its family members, HER3 has impaired kinase activity and relies on dimerization with other ErbB receptors-especially HER2-to initiate downstream signaling pathways such as PI3K/AKT, which are crucial for cell proliferation and survival. Overexpression or activation of HER3 has been implicated in various cancers, including breast, lung, gastric, and colorectal cancers, often contributing to tumor progression, therapeutic resistance, and poor prognosis.
HER3 inhibitors aim to block this signaling, either by preventing ligand binding, dimerization, or downstream signaling activation. Several therapeutic strategies have been explored, including monoclonal antibodies (e.g., patritumab), antibody-drug conjugates (e.g., EO-1022), and bispecific antibodies targeting HER3 and other receptors like HER2 or EGFR. Despite initial challenges due to HER3's lack of intrinsic kinase activity, these agents have shown promise in clinical trials, particularly in tumors with HER3 overexpression or NRG1 fusions. Combination therapies with HER3 inhibitors and other targeted treatments or immunotherapies are also under investigation, potentially offering new options for patients with refractory or resistant cancers.
HER3 Inhibitors Market Overview
The HER3 inhibitors market is experiencing steady growth, driven by the increasing recognition of HER3 as a key driver of tumor progression and resistance in various cancers, including NSCLC, breast, and pancreatic cancers. The market is fueled by advancements in targeted therapies and personalized medicine. Notable developments include the FDA approval of BIZENGRI (zenocutuzumab) in 2024 for NRG1 fusion-positive tumors and promising clinical results from patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate showing efficacy in EGFR-resistant cancers. Other candidates like HMBD-501, HMBD-001, SAL007, and others are in mid-stage trials, expanding the therapeutic landscape. Innovations in companion diagnostics and drug delivery systems are enhancing treatment precision, though challenges like tumor heterogeneity and ligand-independent HER3 activation remain. Overall, the HER3 inhibitors market holds strong potential as both monotherapy and combination strategies evolve to address unmet needs in oncology.
The market is highly competitive with key players including Merck, Hummingbird Bioscience, Endeavor BioMedicines, Elevation Oncology, and others investing heavily in R&D to develop HER3 inhibitors with enhanced potency and safety.
HER3 Inhibitors - Potential Patient Pool
This chapter focuses on the potential patient pool for HER3 inhibitors, covering nearly 10 key indications where HER3-targeted therapies may be applicable. It provides both historical and projected data on the total number of cases, the eligible population for treatment, and estimated treated patients across the 7 major markets (the United States, EU4 - Germany, France, Italy, and Spain - the United Kingdom, and Japan) from 2020 to 2034.
The drug chapter segment of the HER3 inhibitors reports encloses a detailed analysis of approved HER3 inhibitors late-stage (Phase III and Phase II) HER3 inhibitors. It also helps understand the HER3 inhibitor's clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Marketed Drugs
BIZENGRI (zenocutuzumab-zbco): MERUS NV
BIZENGRI is a bispecific antibody that binds to the extracellular domains of HER2 and HER3 expressed on the surface of cells, including tumor cells, inhibiting HER2:HER3 dimerization and preventing NRG1 binding to HER3. BIZENGRI decreased cell proliferation and signaling through the phosphoinositide 3-kinase-AKT-mammalian target of the rapamycin pathway. In addition, BIZENGRI mediates antibody-dependent cellular cytotoxicity. BIZENGRI showed antitumor activity in mouse models of NRG1+ lung and pancreatic cancers.
Zenocutuzumab is the world's first approved HER3-targeted drug and the first FDA-approved therapy for NRG1+ PDAC and NSCLC. It works by targeting and inhibiting the HER3 receptor, a critical driver of cancer progression. The approval is based on promising clinical data, including overall response rate and duration of response, with continued approval contingent on the results of confirmatory trials. BIZENGRI carries a Boxed Warning for embryo-fetal toxicity and has additional warnings for infusion-related reactions, hypersensitivity, interstitial lung disease, and left ventricular dysfunction.
Emerging Drugs
Patritumab deruxtecan (MK-1022): Merck/ Daiichi Sankyo
Patritumab deruxtecan is an investigational antibody-drug conjugate that consists of a fully human anti-HER3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload. In October 2023, Daiichi Sankyo and Merck entered into a global collaboration to jointly develop and commercialize patritumab deruxtecan (HER3-DXd), and other drugs, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.
In December 2021, Daiichi Sankyo announced that the FDA granted breakthrough therapy designation to patritumab deruxtecan, a first-in-class HER3-directed ADC, for treating metastatic or locally advanced EGFR-mutated NSCLC after progression on third-generation TKIs and platinum-based therapies.
HMBD-001: Hummingbird Bioscience
HMBD-001 is a clinical-stage IgG1 antibody designed to target HER3, discovered using Hummingbird Bioscience's proprietary Rational Antibody Discovery (RAD) platform. HMBD-001 is the only anti-HER3 antibody in development that has the potential to fully block both ligand-dependent and -independent HER3 activation and oncogenic signaling, by targeting a key epitope located at the interface where HER3 forms heterodimers with HER2 or EGFR.
In preclinical models evaluating HMBD-001, superior affinity, and more potent tumor growth inhibition compared to existing anti-HER3 antibodies were observed. HMBD-001 is currently in Phase Ib clinical trials for biomarker-selected indications with a strong scientific rationale, which includes squamous non-small cell lung cancer, NRG1 fusions, and HER3 mutations.
HER3-targeted therapies are a rapidly evolving area, with multiple agents in early- and late-stage clinical development. Combination strategies-such as pairing HER3 inhibitors with EGFR TKIs or immune checkpoint inhibitors-are being explored to enhance efficacy and overcome resistance. Biomarker-driven patient selection (e.g., HER3 expression or HER3+ circulating tumor cell count) may further refine the use of these therapies in clinical practice.
Leading companies in the HER3 space such as Merus NV, Merck, Hummingbird Bioscience, Endeavor BioMedicines, EnBio, Callio Therapeutics, Avenzo Therapeutics, and Elevation Oncology are actively developing HER3 inhibitors for various cancers, including breast, NSCLC, pancreatic, prostate, ovarian, colorectal cancers and others. HER3-targeted therapies represent a promising approach to overcoming drug resistance, particularly in tumors where HER3 signaling drives progression and treatment failure.
This section focuses on the uptake rate of potential approved and emerging HER3 expected to be launched in the market during 2025-2034.
HER3 Inhibitor Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.
The presence of numerous drugs under different stages is expected to generate immense opportunity for HER3 inhibitors market growth over the forecasted period.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for HER3 inhibitor therapies.
KOL Views
To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on HER3 inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.
DelveInsight's analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as Johns Hopkins, Sidney Kimmel Cancer Center, and others were contacted.
Their opinion helps understand and validate current and emerging therapy treatment patterns or HER3 inhibitor market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.
In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Continuing Medical Education (CME) program, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.